Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Association of lipoprotein lipase expression with TP53 gene polymorphisms in chronic lymphocytic leukemia cells. | Exp Oncol | 2021 | 34591432 | PubTator, text mining | PubMed |
| New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. | Curr Oncol | 2021 | 34590593 | PubTator, text mining | PubMed |
| Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. | Cell Rep | 2021 | 34587480 | PubTator, text mining | PubMed |
| Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia. | Front Oncol | 2021 | 34568060 | PubTator, text mining | PubMed |
| Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. | Clin Cancer Res | 2021 | 34551904 | PubTator, text mining | PubMed |
| Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner. | J Adv Pract Oncol | 2021 | 34540333 | PubTator, text mining | PubMed |
| Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? | Blood Adv | 2021 | 34525181 | PubTator, text mining | PubMed |
| Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. | Nat Commun | 2021 | 34518531 | PubTator, text mining | PubMed |
| Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). | Clin Lymphoma Myeloma Leuk | 2021 | 34511320 | PubTator, text mining | PubMed |
| Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). | PLoS One | 2021 | 34506616 | PubTator, text mining | PubMed |
| Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential. | Int J Mol Sci | 2021 | 34502399 | PubTator, text mining | PubMed |
| Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients. | Int J Mol Sci | 2021 | 34502260 | PubTator, text mining | PubMed |
| Chronic lymphocytic leukemia in a young population. | Leuk Res | 2021 | 34492597 | PubTator, text mining | PubMed |
| Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants. | PLoS Comput Biol | 2021 | 34491988 | PubTator, text mining | PubMed |
| Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. | Blood Adv | 2021 | 34478505 | PubTator, text mining | PubMed |
| Ribosomal RNA‑depleted RNA sequencing reveals the pathogenesis of refractory Mycoplasma pneumoniae pneumonia in children. | Mol Med Rep | 2021 | 34476502 | PubTator, text mining | PubMed |
| The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. | Curr Opin Oncol | 2021 | 34474439 | PubTator, text mining | PubMed |
| Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers. | EBioMedicine | 2021 | 34461601 | PubTator, text mining | PubMed |
| [Clinical analysis of fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of 43 cases of chronic lymphoblastic leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2021 | 34455740 | PubTator, text mining | PubMed |
| Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data | Turk J Haematol | 2021 | 34448556 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=41